Sept 26 (Reuters) - OSSUR HF ::SAID ON MONDAY THAT IT HAS INITIATED 3 EFFICIENCY INITIATIVES IN THE AREAS OF MANUFACTURING, DISTRIBUTION, AND SOURCING .THE INITIATIVES WILL BE IMPLEMENTED OVER THE NEXT THREE YEARS WHERE ANNUAL COST SAVINGS ARE EXPECTED TO MATERIALIZE GRADUALLY AND AMOUNT TO USD 10 MILLION IN 2020.TOTAL IMPLEMENTATION COSTS ARE EXPECTED TO AMOUNT TO USD 15 MILLION, HEREOF APPROXIMATELY USD 3 MILLION IN THE THIRD QUARTER OF 2017.IN ADDITION, TOTAL CAPITAL EXPENDITURES RELATED TO THE INITIATIVES ARE EXPECTED TO BE AROUND USD 4 MILLION.ÖSSUR INTENDS TO INVEST A PORTION OF THE REALIZED SAVINGS IN R&D.THESE MEASURES DO NOT IMPACT THE FULL YEAR 2017 GUIDANCE AS CO PROVIDES GUIDANCE ON EBITDA MARGIN BEFORE SPECIAL ITEMS.
Sept 14 (Reuters) - LivaNova Plc :LivaNova Plc - Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term.LivaNova Plc - Anticipates compounded annual earnings per share growth in low- to mid-teens from 2017 to 2022.
Sept 7 (Reuters) - Mimedx Group Inc ::MiMedx reports further developments in its civil litigation against former employees.MiMedx Group Inc - co has been aware for some time of an ongoing investigation by department of veterans affairs office of inspector general.MiMedx Group Inc - company is not a target of investigation by department of veterans affairs office of inspector general.MiMedx Group - terminated employee formally withdrew claim that he had previously filed alleging he was fired for supporting channel stuffing claims.MiMedx - additional evidence from litigation confirmed some terminated individuals gave gifts, meals to va employees potentially violating federal law.MiMedx Group Inc - terminated employee testified that all of product at locations where he was assigned was used, none of it was returned.MiMedx Group-also been made aware of various "short sell" theses based on "unfounded allegations" of the terminated employees named in civil litigation.
Sept 1 (Reuters) - Transenterix Inc :Transenterix Inc says entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company, incorporated - SEC filing .Transenterix - As per agreement, co may sell from time to time up to $50 million of co's shares, $0.001 par value per share through Stifel, as sales agent.Transenterix Inc- On August 31, 2017 co terminated controlled equity offerings sales agreement, dated as of February 9, 2016 with Cantor Fitzgerald & Co.
Aug 29 (Reuters) - DIGNITANA AB :DIGNITANA ESTABLISHES CREDIT FACILITY TO SUPPORT INCREASED DEMAND.AGREEMENT PROVIDES A SUBSTANTIAL LINE OF CREDIT TO DIGNITANA AND IS SECURED BY CONTRACTED DIGNICAP INSTALLATIONS IN UNITED STATES.HAS ANNOUNCED TODAY A FINANCIAL AGREEMENT WITH UNION BUSINESS LEASING, INC. OF BOULDER, COLORADO TO PROVIDE DIGNITANA A REVOLVING CREDIT FACILITY.
Aug 28 (Reuters) - Henry Schein Inc ::Henry Schein to acquire Merritt Veterinary Supplies.Henry Schein Inc - expects acquisition to be neutral to its 2017 earnings per share and to be accretive thereafter.Henry Schein Inc - merritt will become part of Henry Schein Animal Health, U.S. Animal health business of Henry Schein Inc.Henry Schein Inc - financial terms were not disclosed..
Aug 28 (Reuters) - Bactiguard Holding AB :Bactiguard appoints new CFO.Says has appointed Cecilia Edstrom, today Senior Vice President Sales and New Business, as acting Chief Financial Officer (CFO).She succeeds Fredrik Jarrsten, who will leave Bactiguard to assume a new CFO role in another company.Says Jarrsten will remain in the company a short period of time to ensure a smooth transition.
Aug 14 (Reuters) - AAP IMPLANTATE AG ::ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO CREATE MORE VALUE.THERE IS NO SET TIME TABLE FOR THIS PROCESS OF EXPLORING STRATEGIC ALTERNATIVES.IS EXPLORING CO-DEVELOPMENT-/LICENSE AGREEMENTS, JOINT VENTURE AGREEMENTS TO CORPORATE TRANSACTIONS (E.G. MERGER, SHARE OR ASSET DEAL, CARVE OUT).
Aug 10 (Reuters) - Cytori Therapeutics Inc :Cytori reports second quarter 2017 business and financial results.Q2 loss per share $0.19.Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Cytori Therapeutics Inc - expects full year 2017 operating cash burn to be higher than 2016.Says Q2 2017 total revenues were $1.5 million compared to $2.8 million for same periods in 2016.Cytori Therapeutics Inc - full year 2017 updated operating cash burn forecasted to be within a range of $20 million to $23 million.
July 28 (Reuters) - Alfresa Holdings Corp <2784.T>:Says co's Saitama-based pharmacy operation wholly owned unit will merge with co's Tokyo-based pharmacy operation wholly owned unit on Oct. 1.Says the Saitama-based unit will be the surviving company .